Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Bevacizumab as Adjuvant Therapy for High-Risk HCC
NCT06958484Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Planned start May 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06958484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958484.